| Filed On | Filing |
|---|---|
| 08 Sep 2026 |
8-K: Results of Operations and Financial Condition
U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027 |
| 03 Aug 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
Loading...
